Carboxypeptidase B2 (CPB2), also known as carboxypeptidase U (CPU), plasma carboxypeptidase B (pCPB) or thrombin-activatable fibrinolysis inhibitor (TAFI), is an
enzyme that, in humans, is encoded by the
geneCPB2.[5][6]
Function
CPB2 is synthesized by the liver[7] and circulates in the plasma as a
plasminogen-bound
zymogen. When it is activated by proteolysis at residue Arg92 by the
thrombin/
thrombomodulin complex, CPB2 exhibits carboxypeptidase activity. Activated CPB2 reduces fibrinolysis by removing the
fibrinC-terminal residues that are important for the binding and activation of
plasminogen.[8][9]
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by
thrombin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates
fibrinolysis.[10]
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
Isozymes
Polymorphisms have been described for this gene and its promoter region. Available sequence data analyses indicate splice variants that encode different isoforms.[10]
^Tsai SP, Drayna D (Dec 1992). "The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13". Genomics. 14 (2): 549–50.
doi:
10.1016/S0888-7543(05)80268-X.
PMID1427879.
^Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U. (2010; edition 8: pages 1833-1834 and 2040-2041) Williams Hematology. McGraw-Hill.
ISBN978-0071621519
^Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M (December 1998). "Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms". Thromb. Haemost. 80 (6): 949–55.
doi:
10.1055/s-0037-1615394.
PMID9869166.
S2CID1803078.
^Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML (May 1999). "Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)". Biochemistry. 38 (20): 6547–58.
doi:
10.1021/bi990229v.
PMID10350473.
Vanhoof G, Wauters J, Schatteman K, et al. (1997). "The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11". Genomics. 38 (3): 454–5.
doi:
10.1006/geno.1996.0656.
PMID8975730.
Matsumoto A, Itoh K, Matsumoto R (2000). "A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus". Eur. J. Neurosci. 12 (1): 227–38.
doi:
10.1046/j.1460-9568.2000.00908.x.
PMID10651877.
S2CID26058321.
Mosnier LO, Lisman T, van den Berg HM, et al. (2002). "The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration". Thromb. Haemost. 86 (4): 1035–9.
doi:
10.1055/s-0037-1616530.
PMID11686321.
S2CID4080586.
Mosnier LO, Meijers JC, Bouma BN (2002). "The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis". Thromb. Haemost. 86 (4): 1040–6.
doi:
10.1055/s-0037-1616531.
PMID11686322.
S2CID21500722.
Mosnier LO, Elisen MG, Bouma BN, Meijers JC (2002). "Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation". Thromb. Haemost. 86 (4): 1057–64.
doi:
10.1055/s-0037-1616533.
PMID11686324.
S2CID32258311.
Morange PE, Aillaud MF, Nicaud V, et al. (2002). "Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers". Thromb. Haemost. 86 (6): 1583–4.
doi:
10.1055/s-0037-1616769.
PMID11776333.
S2CID30051401.
Koschinsky ML, Boffa MB, Nesheim ME, et al. (2002). "Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure". Clin. Genet. 60 (5): 345–9.
doi:
10.1034/j.1399-0004.2001.600504.x.
PMID11903334.
S2CID86724521.
Carboxypeptidase B2 (CPB2), also known as carboxypeptidase U (CPU), plasma carboxypeptidase B (pCPB) or thrombin-activatable fibrinolysis inhibitor (TAFI), is an
enzyme that, in humans, is encoded by the
geneCPB2.[5][6]
Function
CPB2 is synthesized by the liver[7] and circulates in the plasma as a
plasminogen-bound
zymogen. When it is activated by proteolysis at residue Arg92 by the
thrombin/
thrombomodulin complex, CPB2 exhibits carboxypeptidase activity. Activated CPB2 reduces fibrinolysis by removing the
fibrinC-terminal residues that are important for the binding and activation of
plasminogen.[8][9]
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by
thrombin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates
fibrinolysis.[10]
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
Isozymes
Polymorphisms have been described for this gene and its promoter region. Available sequence data analyses indicate splice variants that encode different isoforms.[10]
^Tsai SP, Drayna D (Dec 1992). "The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13". Genomics. 14 (2): 549–50.
doi:
10.1016/S0888-7543(05)80268-X.
PMID1427879.
^Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U. (2010; edition 8: pages 1833-1834 and 2040-2041) Williams Hematology. McGraw-Hill.
ISBN978-0071621519
^Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M (December 1998). "Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms". Thromb. Haemost. 80 (6): 949–55.
doi:
10.1055/s-0037-1615394.
PMID9869166.
S2CID1803078.
^Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML (May 1999). "Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)". Biochemistry. 38 (20): 6547–58.
doi:
10.1021/bi990229v.
PMID10350473.
Vanhoof G, Wauters J, Schatteman K, et al. (1997). "The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11". Genomics. 38 (3): 454–5.
doi:
10.1006/geno.1996.0656.
PMID8975730.
Matsumoto A, Itoh K, Matsumoto R (2000). "A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus". Eur. J. Neurosci. 12 (1): 227–38.
doi:
10.1046/j.1460-9568.2000.00908.x.
PMID10651877.
S2CID26058321.
Mosnier LO, Lisman T, van den Berg HM, et al. (2002). "The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration". Thromb. Haemost. 86 (4): 1035–9.
doi:
10.1055/s-0037-1616530.
PMID11686321.
S2CID4080586.
Mosnier LO, Meijers JC, Bouma BN (2002). "The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis". Thromb. Haemost. 86 (4): 1040–6.
doi:
10.1055/s-0037-1616531.
PMID11686322.
S2CID21500722.
Mosnier LO, Elisen MG, Bouma BN, Meijers JC (2002). "Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation". Thromb. Haemost. 86 (4): 1057–64.
doi:
10.1055/s-0037-1616533.
PMID11686324.
S2CID32258311.
Morange PE, Aillaud MF, Nicaud V, et al. (2002). "Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers". Thromb. Haemost. 86 (6): 1583–4.
doi:
10.1055/s-0037-1616769.
PMID11776333.
S2CID30051401.
Koschinsky ML, Boffa MB, Nesheim ME, et al. (2002). "Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure". Clin. Genet. 60 (5): 345–9.
doi:
10.1034/j.1399-0004.2001.600504.x.
PMID11903334.
S2CID86724521.